PURPOSE: The ACE Inhibitor After Anthracycline (AAA) study is a randomized, double-blind, controlled clinical trial comparing enalapril with placebo to determine whether treatment can slow the progression of cardiac decline in patients who screen positive for anthracycline cardiotoxicity. METHODS: The primary outcome measure is the rate of decline, over time, in maximal cardiac index (in liters per minute per meters squared) at peak exercise; the secondary outcome measure is the rate of increase in left ventricular end systolic wall stress (in grams per centimeters squared). Patients >2 years off therapy and <4 years from diagnosis, aged 8 years and older, were eligible if they had received anthracyclines and had at least one cardiac abnormality identified at any time after anthracycline exposure. RESULTS: A total of 135 patients were randomized to enalapril or placebo. Baseline characteristics were similar across treatment groups. CONCLUSIONS: The AAA study will provide important information concerning the efficacy of using angiotensin-converting enzyme inhibitors to offset the effects of late anthracycline cardiotoxicity.
RCT Entities:
PURPOSE: The ACE Inhibitor After Anthracycline (AAA) study is a randomized, double-blind, controlled clinical trial comparing enalapril with placebo to determine whether treatment can slow the progression of cardiac decline in patients who screen positive for anthracyclinecardiotoxicity. METHODS: The primary outcome measure is the rate of decline, over time, in maximal cardiac index (in liters per minute per meters squared) at peak exercise; the secondary outcome measure is the rate of increase in left ventricular end systolic wall stress (in grams per centimeters squared). Patients >2 years off therapy and <4 years from diagnosis, aged 8 years and older, were eligible if they had received anthracyclines and had at least one cardiac abnormality identified at any time after anthracycline exposure. RESULTS: A total of 135 patients were randomized to enalapril or placebo. Baseline characteristics were similar across treatment groups. CONCLUSIONS: The AAA study will provide important information concerning the efficacy of using angiotensin-converting enzyme inhibitors to offset the effects of late anthracyclinecardiotoxicity.
Authors: Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Soomi Hwang; Michael J Rieder; Amit P Bhavsar; Anne Smith; Shubhayan Sanatani; Karen A Gelmon; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton Journal: Br J Clin Pharmacol Date: 2016-06-30 Impact factor: 4.335
Authors: M Sereno; A Brunello; A Chiappori; J Barriuso; E Casado; C Belda; J de Castro; J Feliu; M González-Barón Journal: Clin Transl Oncol Date: 2008-01 Impact factor: 3.405
Authors: Adriana Albini; Giuseppina Pennesi; Francesco Donatelli; Rosaria Cammarota; Silvio De Flora; Douglas M Noonan Journal: J Natl Cancer Inst Date: 2009-12-10 Impact factor: 13.506
Authors: Saro H Armenian; Melissa M Hudson; Ming Hui Chen; Steven D Colan; Lanie Lindenfeld; George Mills; Aida Siyahian; Sarah Gelehrter; Ha Dang; Wendy Hein; Daniel M Green; Leslie L Robison; F Lennie Wong; Pamela S Douglas; Smita Bhatia Journal: BMC Cardiovasc Disord Date: 2016-10-04 Impact factor: 2.298
Authors: Derek W Edwardson; Rashmi Narendrula; Simon Chewchuk; Kyle Mispel-Beyer; Jonathan P J Mapletoft; Amadeo M Parissenti Journal: Curr Drug Metab Date: 2015 Impact factor: 3.731